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Reducing or eliminating expression of a given gene is likely to
require multiple methods to ensure coverage of all of the genes in
a given mammalian cell. We and others [Furth, P. A., Choe, W. T.,
Rex, J. H., Byrne, J. C., and Baker, C. C. (1994) Mol. Cell. Biol. 14,
5278–5289] have previously shown that U1 small nuclear (sn) RNA,
both natural or with 5 end mutations, can specifically inhibit
reporter gene expression in mammalian cells. This inhibition occurs
when the U1 snRNA 5 end base pairs near the polyadenylation
signal of the reporter gene’s pre-mRNA. This base pairing inhibits
poly(A) tail addition, a key, nearly universal step in mRNA biosyn-
thesis, resulting in degradation of the mRNA. Here we demonstrate
that expression of endogenous mammalian genes can be effi-
ciently inhibited by transiently or stably expressed 5 end-mutated
U1 snRNA. Also, we determine the inhibitory mechanism and
establish a set of rules to use this technique and to improve the
efficiency of inhibition. Two U1 snRNAs base paired to a single
pre-mRNA act synergistically, resulting in up to 700-fold inhibition
of the expression of specific reporter genes and 25-fold inhibition
of endogenous genes. Surprisingly, distance from the U1 snRNA
binding site to the poly(A) signal is not critical for inhibition,
instead the U1 snRNA must be targeted to the terminal exon of the
pre-mRNA. This could reflect a disruption by the 5 end-mutated U1
snRNA of the definition of the terminal exon as described by the
exon definition model.
mutant U1 snRNAs  gene expression inhibition  polyadenylation
inhibition
Nearly all mature eukaryotic mRNAs, histone mRNAs beingthe only significant exception, contain a poly(A) tail that
functions to control mRNA degradation (1, 2), translation
efficiency (3, 4), and possibly mRNA export (5). The poly(A) tail
is posttranscriptionally added to pre-mRNAs in the nucleus by
a two-step reaction called cleavage and polyadenylation. In the
first step, the pre-mRNA is endonucleolytically cleaved into two
molecules at the cleavage site, also called the poly(A) site (6). In
the second step, a poly(A) tail of 250 adenosine residues (70
in Saccharomyces cerevisiae) is added to the 3 end of the
upstream fragment by the enzyme poly(A) polymerase, whereas
the downstream pre-mRNA fragment is degraded. Although
much work remains to be done, the reaction mechanism is
relatively well understood, and the major pre-mRNA sequence
elements and nearly all of the polypeptides present in the
cleavagepolyadenylation machinery have been identified in
both S. cerevisiae and mammalian cells (6–8).
Regulation of poly(A) tail addition (7, 8) typically involves the
choice between two or more poly(A) sites on a single pre-
mRNA, resulting in mRNAs differing either in their coding
regions or 3 UTR sequences that may affect mRNA stability,
localization, and translatability (1–8). A second, less common
way to control poly(A) tail addition is by an ‘‘on–off’’ switch
mechanism whereby a single poly(A) site is either active or
inactive. The U1A splicing factor represents the best understood
example of this type of regulation, where excess U1A protein
negatively autoregulates its own synthesis by inhibiting poly(A)
tail addition to its own pre-mRNA (9). The mechanism involves
dimerization of U1A on the U1A pre-mRNA, resulting in the
formation of a binding pocket that interacts with and inhibits
poly(A) polymerase (9, 10). Inhibition of poly(A) tail addition to
the U1A pre-mRNA leads to reduced U1A mRNA and protein
levels. Importantly, U1A selectively inhibits only the poly(A)
addition step, which presumably allows the cleavage step to
endonucleolytically remove downstream cryptic poly(A) sites
that may become activated during the regulation.
A second example of such an on–off regulation is where the
U1 small nuclear ribonucleoprotein (U1 snRNP) particle, nor-
mally involved in recognition of the 5 splice site sequence (5ss)
during pre-mRNA splicing, binds upstream of a poly(A) site
inhibiting its usage (11–14). Certain papillomaviruses use this
type of regulation during early stages of infection to repress late
gene expression via inhibition of the activity of the late poly(A)
site by a U1 snRNP:5ss complex (11, 14). The inhibitory
mechanism is similar to U1A autoregulation and involves two
regions of the U1 snRNP-specific U170K protein that bind to
and inhibit poly(A) polymerase (14). An interesting and related
example is in HIV, in which a poly(A) site in the 5 LTR is
maintained in an inactive state by the downstream binding of U1
snRNP, through a splicing independent mechanism that is still to
be determined (15).
Mammalian U1 snRNP contains 10 polypeptides bound to the
164-nt U1 snRNA (Fig. 1A) and functions primarily to direct
early steps in spliceosome formation by binding to the pre-
mRNA exon–intron boundary (16, 17). Nucleotides 2–11 of the
5 end of U1 snRNA base pair to the 5ss of the pre-mRNA.
There are a number of examples in which expression of 5
end-mutated U1 snRNA leads to assembly of 5 end-mutated U1
snRNP able to base pair to target sequences thereby changing
the pattern of pre-mRNA processing of the targeted gene.
Examples include suppressor U1 snRNAs (i.e., U1 snRNPs) (18,
19) that bind to and activate splicing at nonphysiological 5 splice
sites as well as 5 end-mutated U1 snRNAsU1 snRNPs that
bind the 3 UTR inhibiting expression of exogenous and stably
expressed reporter genes (11–13). Here, for the first time, we use
5 end-mutated U1 snRNAsU1 snRNPs to inhibit expression of
endogenous genes in mammalian cells (rat and human) and
demonstrate that two U1 snRNAs base paired to a single target
gene’s pre-mRNA act synergistically, resulting in up to 700-fold
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inhibition of the expression of specific reporter genes and 25-fold
inhibition of endogenous genes. We determine the inhibitory
mechanism and establish a set of rules to use this technique,
including the finding that the U1 snRNA must be targeted to the
terminal exon of a pre-mRNA with a polyadenylation signal.
Materials and Methods
HeLa cells (14) and Ros 172.8 cells (13) were passaged and
cultured under standard conditions. For details, see Supporting
Text, which is published as supporting information on the PNAS
web site, www.pnas.org.
Stable cell lines were produced as described (12, 13) with
neomycin as the selection reagent. Luciferase assays were done
according to the manufacturer’s directions. Luciferase activity
was measured in a Berthold luminometer (Lumat LB 9507).
Whole cell lysates used for Western blotting were prepared by
lysis of cells in buffer containing 150 mM NaCl, 0.1% Triton, 50
mM Tris (pH 8), and 0.1 mM EDTA, followed by a brief
sonication, centrifugation for 5 min at 20,000 g, and collection
of the supernatant. Chemiluminescence Western blots were
performed and quantitated as described (14) with detection
reagents from Amersham Pharmacia and Immobilon-P nylon
membrane from Millipore. Antibody dilutions were 1:2,000 for
the anti-aryl sulfatase A (ASA) antibody (kindly provided by
P. Manowitz, University of Medicine and Dentistry, Piscataway,
NJ), 1:10,000 for the anti-GAPDH antibody (Chemicon), and
1:5,000 for the anti-osteocalcin antibody (Diagnostic Systems
Laboratories, Webster, TX). Northern blotting was done as
described (12, 13) with probes generated by the random priming
labeling method. The 900-nt Collagen 1a1 probe was derived
from the C-terminal and 3 noncoding region of the rat Collagen
1a1 gene, which is the least conserved part between collagen
genes. The 500-nt osteocalcin probe was derived from a mouse
osteocalcin cDNA, which is 89% identical to the rat gene.
Results
Rationale. Even if we have successfully used 5 end-mutated U1
snRNAs to inhibit the expression of reporter genes, we (and
others) had two concerns about the application of the technique
to endogenous genes: (i) the lack of explicit rules for choosing
the target site on the pre-mRNA, and (ii) the significant
potential for cytotoxicity of long-term, stable expression of 5
end-mutated U1 snRNAs in cells. Cytotoxicity could arise by the
5 end-mutated U1 snRNA, either inducing errors in pre-mRNA
splicing or binding near and inhibiting the poly(A) signals of
essential, nontargeted genes. Thus we first focused on establish-
ing an explicit set of rules by determining (i) the effects of the
location [distance to the poly(A) site and terminal exon versus
upstream exons or introns] of the target site, (ii) the effects of
the number of target sites on a given pre-mRNA, (iii) the effects
of secondary structures in the target sites or between the target
site and the polyadenylation site, and (iv) the importance of the
presence of polyadenylation sequences to get inhibition. The
results of this analysis are shown in Figs. 1–3.
Assay to Measure Inhibition. Fig. 1 A is a schematic of the strategy
where either natural or 5 end-mutated U1 snRNA assembles
into a U1 snRNP that base pairs to a target sequence in the
terminal exon of the target gene, leading to inhibition of poly(A)
tail addition. Advantages of this strategy include that (i) U1
snRNP proteins are highly abundant, and (ii) the natural activity
of U1 snRNAU1 snRNP to base pair to pre-mRNA and to
localize to the desired cellular compartment is exploited. To
systematically measure the degree and specificity of inhibition,
we performed transient transfections with the dual luciferase
reporter assay system (Promega), where the Renilla luciferase
gene would be targeted for inhibition and a cotransfected firefly
luciferase gene would not be targeted. Because both luciferase
activities are measured in the same transfected cell lysate, this
assay provides a more accurate internal control and normaliza-
tion of data than assays based on normalization to cotransfected
-galactosidase or CAT control genes. The pRL-simian virus 40
(pSV) (Promega) Renilla reporter plasmid was modified by
introducing a 10-nt-long, consensus, wild-type (WT) or mutant
(MT) 5ss 87 nt upstream of the poly(A) signal sequence
(AAUAAA) to produce the pSV87WT and pSV87MT plas-
mids, respectively (Fig. 1B). The particular 3-nt mutation in the
MT5ss inhibits splicing in vitro and in vivo and does not bind
purified U1 snRNP in vitro (14, 17). pSV87MT and pSV had
similar Renilla expression levels, whereas pSV87WT had a
32.5-fold reduction in Renilla activity (Fig. 1B). Because the
pSV87WT and pSV87MT plasmids differ by only 3 nt, we
Fig. 1. Strategy and reporter system. (A) Schematic of strategy. Shown is the
composition of endogenous U1 snRNP comprised of three U1 snRNP-specific
proteins (U1A, U1C, and U170K), U1 snRNA (black line) with stemloops 1–4 and
the Sm core consisting of seven Sm proteins bound to the U1 snRNA–Sm site.
Also shown is a generic mammalian pre-mRNA containing in its 3 UTR a
nonphysiological U1 snRNP binding site bound to U1 snRNP containing a 5
end-mutated U1 snRNA. Coding regions are shaded boxes, introns are dotted
lines, the 5 UTR and 3 UTR are solid lines, and the double arrow indicates
sequences that direct pre-mRNA cleavage and poly(A) tail addition. The U1
snRNP pre-mRNA complex inhibits, in a gene-specific manner, the addition of
the poly(A) tail, thereby preventing maturation of the pre-mRNA leading to
reduced mature mRNA levels. (B) Establishment of inhibition of reporter
mRNA biosynthesis. pGL2 (Promega), expressing the firefly luciferase gene
(Photinus pyralis), was cotransfected with all of the Renilla expression reporter
plasmids. The Renilla light units were normalized to the firefly light units,
thereby controlling for transfection efficiency, cell recovery, and lysis after
transfection, a distinct advantage over other reporter assays. pSV (pRL-SV40,
Promega) contains a SV40 promoter-enhancer, a  globin intron, the coding
region for Renilla luciferase (RL), and an SV40-derived (SV) 3 UTR and cleav-
age and polyadenylation signal. The pL3 construct is identical to pSV except
the 3 UTR and cleavage and polyadenylation signal was derived from ade-
novirus L3 (L3; wavy line). pSV87WT and pSV87MT are a pair of matched
plasmids containing either a WT U1 snRNA binding site (solid box) or the MT
(solid box) positioned 87 nt upstream of the AAUAAA sequence. Likewise,
pL324 represents a pair of matched plasmids containing either a WT (pL3
24WT) or MT (pL324MT) site positioned 24 nt upstream. A total of 2.5 g of
each construct, along with 2.5 g of pGL2 internal control, was transfected
into 106 HeLa cells on a 10-cm plate, and after 48 h the cells were harvested and
luciferase levels were measured with the Promega Dual Luciferase assay. The
Renilla light units were normalized to the cotransfected firefly light units, and
the results from three or more independent experiments are shown. Standard
deviations (not shown) were15% in all cases. The fold inhibition is the ratio
of normalized Renilla activity of the MT5ss plasmid to the matching WT5ss
plasmid. Symbols are as in A.
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conclude that the presence of the WT5ss, i.e., a U1 snRNAU1
snRNP binding site, confers specific inhibition of the expression
of the Renilla gene.
Parameters Affecting Inhibition. Systematic increases in the length
of the U1 snRNA binding site from 10 nt up to 16 nt had only
slight reductions in the efficiency of inhibition, meaning potent
(10-fold in all cases) specific inhibition was still observed.
However, when U1 snRNA binding sites were7 nt or when the
5 end of U1 snRNA was extended to interact with 25 or 50 nt
of Renilla mRNA, no inhibition was observed (data not shown).
Therefore, we kept the binding site at 10 nt throughout this work.
We found inhibition does not depend on the adjacent simian
virus 40 (SV40)-derived flanking sequences, because their re-
placement with corresponding sequences from adenovirus L3
(pL324 in Fig. 1B) or by a synthetic cleavage and polyadenyl-
ation signal (pSPA20; see Fig. 3) gave similar levels of inhibi-
tion. The generality and robust nature of the U1 snRNA
inhibitory strategy is underscored by the fact that similar levels
of inhibition were observed when (i) these constructs were
transfected into 25 different mammalian cell lines (e.g., HeLa,
COS-1, BHK, K562, 293F, Jurkat, 3T3, etc.), (ii) the U1 snRNA
binding site was inserted in the firefly luciferase reporter instead
of the Renilla reporter, (iii) the time of transfection was varied
from 24 to 72 h, and (iv) the amount of transfected reporter gene
was varied across a 600-fold range (data not shown).
Effects of Increased Distance, Multiple Binding Sites, and Introns.
Even if a 20- to 30-fold inhibition (reducing protein levels down
to 3–5%) was respectable compared with either antisense tech-
niques (20) or RNAi (21, 22), we decided to test whether
additional U1 snRNA binding sites or their relative distance to
the polyadenylation signal would affect their inhibitory activity.
With increasing distance, only a very gradual reduction in
inhibitory activity was observed even when the binding sites were
1,190 nt upstream of the polyadenylation signal in the 5 UTR
(Fig. 2A). This surprising ‘‘long-distance’’ inhibition suggests to
us that even if poly(A) signals are being targeted, the inhibition
could be mediated by the disruption of the definition of the
terminal exon (see Discussion). In all cases, two or more binding
sites were better than one, and their inhibitory activities were
synergistic instead of being additive (Fig. 2 A). This synergistic
inhibition was observed regardless of whether the binding sites
were placed in tandem (6 nt apart) or 171 nt apart (the
pL319524 pair of constructs). Increasing from two binding
sites to three [Fig. 2 A gives the example of pSV(145)3] further
increased the level of inhibition; however, four binding sites was
not better than three (data not shown). We note here that this
remarkable increase in inhibition could also be explained as a
stochastic process in which the two binding sites act indepen-
dently and the resulting fold inhibition is the fold inhibition of
one site multiplied with that of the other site. Also, insertion of
an intron, but not a mutated intron, downstream of the binding
site negated the inhibition [pL3(1190)2wtInt is shown in Fig.
2A as an example]. Because the intron had no effect when
inserted upstream, we conclude that U1 snRNA inhibits poly(A)
tail addition only when base paired in the 3 terminal exon of the
pre-mRNA, an idea consistent with the exon definition model
(23) and already supported by our earlier work (12, 13) and by
data in Fig. 4C.
Effect of RNA Secondary Structure. In the context of splicing, there
are many examples where pre-mRNA secondary structures
(usually stem structures) inhibit the splicing activity of a WT5ss
(19, 24). Fig. 2B summarizes results where the placement of a U1
snRNA binding site in a secondary stem structure caused
complete loss of inhibitory activity. Stem structures placed
adjacent to the U1 snRNA binding sites had either a minor (Fig.
2B) or no effect (Fig. 3, the pHistSPA20 pair of plasmids) on
inhibition. The control set of plasmids, containing the mutant U1
snRNA binding site placed within the same type of stem
structures, showed little change in expression, indicating such
structures do not intrinsically affect Renilla expression.
Only ‘‘AAUAAA-Type’’ of Poly(A) Signals Are Inhibited. Although it is
thought that U1 snRNA binding to the target mRNA inhibits the
polyadenylation machinery that utilizes the AAUAAA sequence
(11–14), a polyadenylation-unrelated mechanism could also be
involved. It is possible that U1 snRNP binding could (i) retain
pre-mRNA in the nucleus, (ii) inhibit mRNA-related processes
by antisense interference, (iii) remove the cleavage and polyad-
enylation sequences by activation of splicing in the 3UTR by the
3 UTR-bound U1 snRNP, or (iv) destabilize mRNA, which
could occur by any of a number of processes. Also, it was
important to directly test whether classical polyadenylation
sequences are required for inhibition. There are many viral
Fig. 2. Parameters affecting inhibition. (A) Effects of distance and number
of binding sites on the level of inhibition. In every case, a pair of matched
plasmids was constructed where 1, 2, or 3 binding sites (solid boxes) were
positioned in various parts of the pre-mRNA as indicated. For each plasmid, the
U1 snRNA binding sites were all WT or all MT. Transfection assays were done
as described in Fig. 1B. Plasmids beginning with the letters ‘‘pSV’’ or ‘‘pL3’’
contain SV40 or adenovirus L3 3UTR sequences, respectively, as in Fig. 1B. For
the pL3(1190)2wtInt and pL3(1190)2mtInt matching plasmids, a WT or a
5ss3ss mutated intron was inserted in the 3 UTR of the Renilla gene. For
both intron-containing constructs, alternative splicing was avoided by design-
ing the U1 snRNA binding sites located in the 5UTR to be poor matches to U6
snRNA. Ribonuclease protection experiments demonstrate that the WT intron
was spliced as expected (data not shown). Note that a value of 1.0 represents,
by definition, no inhibition. Note that standard deviations were 15% in all
cases. (B) The effect of target accessibility and RNA secondary structure on
inhibition is shown. In each case, a pair of matched plasmids was constructed
where one or two binding sites (solid boxes) were positioned adjacent to or
within stem loop structures. For each plasmid, the U1 snRNA binding sites were
all WT or all MT. Transfection assays and standard deviations (15% in each
case) were done as described in Fig. 1B. The binding sites in pSV145inSL and
pSV(145)2inSL are able to form a stem loop structure with adjoining pre-
mRNA sequences, whereas the binding sites in pSV145SL and pSV
(145)2SL are adjacent to (6 nt apart) but not within the stem loop structure.
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mRNAs that are polyadenylated by a molecular mechanism that
is distinct from the classical ‘‘AAUAAA’’ type of polyadenyla-
tion (25). There are several mRNAs whose 3 end processing
does not depend on the polyadenylation machinery and that do
not have a poly(A) tail, with histone mRNAs being the best
characterized of this type (26). Furthermore, it would be of
interest to know whether U1 snRNA can inhibit the expression
of polymerase I and polymerase III transcripts.
In Fig. 3 we analyzed the involvement of the polyadenylation
machinery in inhibition. First we note that dot-blot and RNase
protection assays showed a decrease in the amount of poly(A)
Renilla mRNA levels only for those constructs containing a U1
snRNP binding site (see Fig. 5, which is published as supporting
information on the PNAS web site). This decrease in mRNA
levels correlates with the Renilla luciferase activity lending
support to a polyadenylation-inhibition-based mechanism. To
check whether polyadenylation sequences are important, we
replaced the 3 UTR and cleavage and polyadenylation se-
quences of the pSV plasmid with sequences containing the
histone 3 end processing signals to produce the pHist plasmid
(Fig. 3). Most histone mRNAs lack a poly(A) tail and form their
3 ends by an entirely different reaction mechanism that requires
a histone stem loop sequence and a binding site for U7 snRNP
(26). Transfection of the pHist plasmid resulted in efficient
Renilla expression, and as expected, the mRNA produced lacked
a poly(A) tail as measured by dot-blot analysis of poly(A) and
poly(A) fractions (see Fig. 5). Insertion of one or two U1
snRNA binding sites into pHist did not affect Renilla expression
(Fig. 3). Inhibitory activity was restored, however, when the
histone processing signals were replaced by an artificially strong,
synthetic cleavage and polyadenylation sequence (SPA; ref. 27)
as found in the pSPA and pSPA20 plasmids. We excluded the
possibility that the histone stem loop structure itself was masking
the inhibitory activity of the U1 snRNA binding site by observing
inhibition in the pHistMTSPA20 plasmids where the U7
binding site was inactivated by deletion. This result is all the more
remarkable because it strongly supports the idea that U1 snRNA
specifically inhibits poly(A) sites, but not having a significant
effect on mRNA export, stability, or translatability because it is
present in the 3 UTRs of the normally expressed, mature
mRNAs transcribed from the pHist20WT and pHist(20WT)2
plasmids. We also determined that U1 snRNA binding sites
inserted into the 5s rRNA transcript (Pol 1) or the U6 snRNA
transcript (Pol 3) had no effect on their relative expression (data
not shown). Thus, we conclude that U1 snRNA specifically
inhibits AAUAAA type of polyadenylation and will not be
useful for inhibition of other types of RNA transcripts.
Inhibition of Expression of Endogenous Genes. As diagrammed in
Fig. 4A, we targeted the mRNA of endogenous genes with 5
end-mutated U1 snRNA transgenes designed to recognize a
10-nt-long sequence in the 3 terminal exon. Even if the binding
site sequence is not long enough to be completely unique, the
inhibition only works in 3 terminal exons and where the RNA
is unstructured. Because inhibition levels are limited by trans-
fection efficiencies (a 90% transfection rate can at most give a
10-fold inhibition), we used the 293F human fibroblast cell line
where 95–98% of transfection efficiencies are routinely obtained
as confirmed by fluorescence-activated cell sorter analysis of a
GFP reporter plasmid. Note that we transfected different
amounts of the U1 snRNA transgene because increased amounts
of 5 end-mutated U1 snRNA results in increased inhibition.
Transfection of 14 g of each anti-ASA U1 snRNA plasmid
individually resulted in 7- to 8-fold levels of inhibition of the ASA
protein as measured by Western blotting (Fig. 4B, lanes 4 and 5).
Note that transfection of 7 g of each anti-ASA U1 snRNA
plasmid individually gave 3-fold inhibition (data not shown). In
contrast, cotransfection of 4 or 7 g of each transgene together
resulted in synergistic inhibition levels of 15- or 24-fold, respec-
tively (Fig. 4B, lanes 6 and 7), far better than inhibition levels
seen with the corresponding micrograms of each transgene
alone. Use of 14 g of plasmid did not further increase the
inhibition, and no inhibition was observed when control U1
snRNA transgenes were expressed either alone (Fig. 4B, lanes 8
and 9) or together (data not shown). Inhibition was specific, as
reprobing the same Western blot showed no changes in the level
of either GAPDH or -tubulin, and long exposures of the
Western blot failed to detect truncated ASA protein, as can
happen with antisense oligodeoxynucleotides (data not shown)
(28). It was also possible that the anti-ASA U1 snRNAs were
inhibiting expression by inducing aberrant splicing. Indeed, Niwa
et al. (29) observed loss of polyadenylation and exon skipping
when U1 snRNA sites were placed in the terminal exon (see
Discussion for more details). To look for aberrant splicing we
performed a battery of RT-PCR and length measurement
poly(A) tail assays and found none (see Fig. 6, which is published
as supporting information on the PNAS web site). Because
aberrant splicing could remove the primer binding sites used for
these PCR-based assays, we cannot formally rule out the pos-
sibility that U1 snRNA binding sites activate aberrant splicing.
We next determined whether stable expression of 5 end-
mutated U1 snRNA would lead to stable reduction in two genes
(Fig. 4A), osteocalcin (OC), and collagen 1a1 (COL), found in
Ros 172.8 cells (rat bone). We consider this a rigorous test of
the method because these genes are highly expressed and any
potential deleterious effects of the 5 end-mutated U1 snRNA
would become apparent, as the cells are stably expressing the 5
end-mutated U1 snRNPs. Such toxicity had been observed
previously by another group, though in that case the stably
expressed, 5 end-mutated U1 snRNAs were participating in
splicing, not polyadenylation inhibition (30). As shown in the
Northern and Western blots of Fig. 4C, stable expression of
anti-OCU1 snRNA (targeting the OC pre-mRNA) resulted in
a specific 15-fold decrease in OC mRNA levels and a corre-
sponding 15-fold decrease in the OC polypeptide with no
changes in the levels of control mRNAs or polypeptides. Like-
wise, the stable expression of anti-COLU1 snRNA (targeting
the COL pre-mRNA) resulted in a specific 30-fold decrease in
Fig. 3. Inhibitory mechanism targets poly(A) signals. The U1 snRNA binding
site inhibits poly(A) signal-directed 3 end processing but not histone 3 end
processing. Transfection assays and quantitation were done as described in
Fig. 1B. pHist replaces the 3 UTR and cleavage polyadenylation signals of the
pSV plasmid with the histone 3 end processing signals consisting of a histone
stem loop and U7 snRNP binding site. As in Fig. 1, pHist20 represents a pair
of matched plasmids containing one WT or MT U1 snRNA binding site placed
20 nt upstream of the histone stem loop. pHist(20)2 represents a pair of
matched plasmids containing two WT or MT U1 snRNA binding sites. pSPA
replaces the histone 3 end processing signals with artificially strong cleavage
and polyadenylation sequences. pSPA20 represents a pair of matched plas-
mids containing one WT or MT binding site. Likewise, pHistMTSPA20 is a
matching pair of WTMT plasmids containing both types of processing signals
except the histone signal is inactivated by deletion of the U7 binding site. Note
that standard deviations were 15% in all cases.
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COL mRNA (Fig. 4C) and a corresponding 10-fold decrease in
the COL polypeptide (data not shown). The fact that no aberrant
signals were visible in the Northern blots suggests that aberrant
splicing or activation of alternative poly(A) sites was either not
occuring or occuring at a relatively low level. No changes in the
expression of either OC or COL were observed in the control
stable cell line (U1wt), and all three stable cell lines exhibited
normal growth phenotypes. Thus, the stable expression of 5
end-mutated U1 snRNA leads to permanent, inheritable reduc-
tion in the expression of target endogenous genes. One of our
future goals is to stably express multiple U1 snRNAs targeted to
a single endogenous gene, which will require usage of two
different selection markers and two different tagged U1 snRNAs
so as to simultaneously monitor expression of the different 5
end-mutated U1 snRNAs.
Discussion
A protocol along with information on how to obtain the plasmids
to use the U1 snRNA method can be found at www.rci.
rutgers.edugundersn. Essentially, a plasmid harboring the 5
end-mutated U1 snRNA gene is constructed through a routine
cloning step and used for either transient expression or produc-
tion of stable cell lines. Although the data show that this
technique is gene-specific, the overall specificity of this method
and of other gene-inhibitory techniques remains an unresolved
issue that will best be addressed with microarray-based ap-
proaches. Ideally, we could tune the inhibition of a given gene by
varying the number and RNA binding capacities of the 5
end-mutated U1 snRNAs or by developing an inducible U1
snRNA promoter. Note that inhibition of endogenous genes by
transient transfection is less efficient than with stable cell lines
because of (i) limits on transfection efficiency (e.g., a 90%
transfection efficiency can at best lead to a 10-fold inhibition)
and (ii) the time required for the transiently transfected U1
snRNA gene to be transcribed, assembled into U1 snRNP, and
imported into the nucleus.
U1 snRNA Inhibition and the Exon Definition Model. It was surprising
that U1 snRNA inhibited gene expression even when placed far
upstream (up to 1,190 nt) of the AAUAAA poly(A) signal. This
inhibition could reflect a direct, but ‘‘long-distance,’’ interaction
between 5 end-mutated U1 snRNP and the poly(A) signals.
Alternatively, this long-distance inhibition could result from
disruption of the definition of the terminal exon as described in
the exon definition model (23, 29). This model as applied in
higher eukaryotes, proposes that exons, as opposed to much
longer introns, are recognized by the splicing machinery through
interactions bridging from the 5ss back to the upstream 3ss of
the same exon (23). This model holds true for internal exons, but
for the first and last exons it has to be modified in that the first
exon is defined by interactions between the 5 CAP and the first
5ss, while the last, terminal exon is defined by interactions
between the last 3ss and the downstream poly(A) signal. It is
with the definition of this terminal exon that we focus on.
Experimental data supporting terminal exon definition includes
the observation that mutations in the poly(A) signal
(AAUAAA) reduce splicing of the adjacent terminal intron but
not other internal upstream introns, and likewise, mutations in
the terminal 3ss reduce the activity of the poly(A) signal
(reviewed in ref. 23). We propose that assembly of an artificial
5 end mutated U1 snRNAU1 snRNP bound anywhere within
the terminal exon disrupts the terminal 3sspoly(A) signal
interactions. Inhibition of terminal exon definition would lead to
an incompletely processed, immature pre-mRNA that is even-
tually degraded. This explanation, as opposed to one invoking a
simple direct inhibition of the poly(A) signal, predicts that
distance from the binding site of 5 end-mutated U1 snRNA to
Fig. 4. U1 snRNA transgenes target inhibition of endogenous genes. (A) The
schematic is of the 3 end of the pre-mRNA for three target genes: human ASA,
rat osteocalcin, and rat collagen 1a1 with the symbols as described in Fig. 1A.
Shown are the binding sites for two different anti-ASA U1 snRNA transgenes
(designated antiASA1U1 and antiASA2U1) each directed to bind 10 nt in
different parts of the 3 UTR of the ASA pre-mRNA. Also shown are the binding
sites for the anti-osteocalcin U1 snRNA transgene (anti-OCU1) and the anti-
collagen 1a1 U1 snRNA transgene (anti-COLU1). The numbers are the positions
relative tothepolyadenylationsignal. (B) Synergistic inhibitionofASAexpression
by two anti-ASA-specific U1 snRNA transgenes. Western blot is of whole-cell
lysates from cells transiently transfected with the indicated U1 snRNA transgenes
ormock-transfectedcells (lanes1–3).Plasmidabbreviationsareas inFig.4A. Lanes
3–9 each contain 10 g of transfected cell lysate where either one U1 snRNA
transgene (lanes 4, 5, 8, and 9) or two different U1 snRNA transgenes (lanes 6 and
7) were transfected as indicated. Lanes 1–3 each contain 0.5, 2.5, and 10 g of
lysate, respectively, from mock-transfected cells to gauge the sensitivity of the
ECL-basedWesternblot.TheWesternblotwasprobedwithananti-ASAantibody
and then stripped and reprobed for GAPDH or alpha-tubulin as a control (data
not shown). Indicated in lanes 4–7 are the ‘‘fold inhibition of ASA’’ (from three
independent transfections) as compared with lane 3, where each ASA signal was
first normalized to the levels of GAPDH. Lanes 8 and 9 had no inhibition of ASA
as compared with lane 3. The U1 control plasmid in lane 8 is a 5 end-mutated U1
snRNA designed to recognize an internal exon of the ASA gene, whereas the
‘‘U1wtMsc tag’’ plasmid in lane 9 is an additional control that expresses U1
snRNA with a WT 5end. All anti-ASAU1 snRNA plasmids have a mutation in stem
loop3allowingus tomonitor their levelofexpressionbyreverse transcription. (C)
Stableexpressionof singleU1snRNAtransgenes specifically inhibitsexpressionof
osteocalcinandcollagen1a1 inRos172.8cells, a ratosteosarcomaosteoblast cell
line. Three neomycin-resistant stable cell lines were produced from Ros 172.8
cells that stably express different U1 snRNA genes. Anti-COLU1 snRNA is de-
signed to target the rat collagen 1a1 gene, anti-OCU1 snRNA is designed to
target the rat osteocalcin gene, and U1wt is a control that expresses WT U1
snRNA. Lanes 1–3 and 4 and 5 are two separate Northern blots of total RNA taken
from each stable cell line as indicated and were probed to detect both the
osteocalcin and collagen 1a1 mRNAs (lanes 1–3) or just the osteocalcin mRNA
(lanes 4 and 5). The arrows indicate the positions of the mRNAs and rRNAs. Lanes
6 and 7 are a Western blot probed with an anti-osteocalcin antibody where each
lane contains 20 g of total cellular extract from stable cells expressing tagged
U1wt snRNA (lane 6) or tagged anti-OCU1 snRNA (lane 7).
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the poly(A) signal will have at most a minor role in inhibition,
a prediction that matches our observations in Fig. 2.
Do Mutant U1 snRNAs Induce Aberrant Splicing? It is possible that
the 5 end-mutated U1 snRNAs inhibit expression by inducing
aberrant splicing. However, when we target endogenous genes,
we chose the mutant U1 snRNA binding sites so that they cannot
splice, or at least would not be predicted to splice. In all cases
shown in Fig. 4, the U1 snRNA binding sites would be ‘‘bad’’ for
splicing because (i) they lack the canonical GU at the exon–
intron boundary and (ii) they lack a good binding site for U6
snRNA and U5 snRNA. Of course it is possible that the binding
could shift up- or downstream by a few bases and activate
aberrant splicing. Thus, we cannot rule out by design only that
a mutant U1 snRNA activates aberrant splicing. Indeed, there is
precedent for this, as Niwa et al. (29) observed loss of polyad-
enylation and exon skipping when U1 snRNA sites were placed
in the terminal exon. Although we performed extensive RT-PCR
and length measurement poly(A) tail analysis (see Fig. 6) and
failed to detect aberrant splicing, we cannot rule out that it
occurs. We observe inhibition even when the the U1 snRNP
binds1,000 nt away from the 3ss (Figs. 1 and 2), whereas Niwa
et al. (29) reported that inhibition and exon skipping were lost
when the last 3ss and the downstream U1 snRNA site were
300 nt apart. So why is it that we do not observe a 300-nt-long
distance constraint in the data presented here? We note that
Niwa et al. produced the different spacing mutants by inserting
plasmid sequences into their terminal exon near the U1 binding
site. Thus, they cannot rule out that their results reflect changes
in the secondary structure of the pre-mRNA that mask the U1
binding site.
Concluding Remarks. Although we have not examined this exper-
imentally, the U1 snRNA-based approach compares favorably
with antisense-based inhibition (20) or RNAi (21, 22, 31, 32).
The 700-fold inhibition is the highest level yet published for a
reporter gene. For endogenous genes, the 15-fold inhibition with
one stably expressed U1 snRNA or the 25-fold inhibition with
two transiently expressed U1 snRNA genes, are also respectable.
Although this method targets only the 3 terminal exon, that
limitation has the benefit that restoration of the protein or
mutant versions thereof is relatively straightforward with a
transgene with a different 3 UTR, which allows for control of
the phenotypes observed with the inhibition. Finally, we note
that stably expressed, 5 end-mutated U1 snRNA can target a
reporter gene while not inhibiting a nearly identical reporter
gene differing by a single nucleotide (3), thus allowing targeted
inhibition of a dominant negative gene while not targeting the
homologous functional copy of the gene. In conclusion, repro-
grammed U1 snRNA transgenes are potent and specific inhib-
itors of gene expression in mammalian cells that provide re-
searchers with a powerful tool to study mammalian gene
function.
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